Még nem toboroz
A Study of Ivonescimab Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC
2026-526300-67-00· 3. fázis· Summit Therapeutics Inc.· Forrás
Toboroz
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
2024-518365-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Még nem toboroz
Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients
NCT07004413· 3. fázis· Charite University, Berlin, Germany· Forrás
Toboroz
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial
2025-521209-42-00· 4. fázis· Fondazione GONO G.I.· Forrás
Toboroz
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· 3. fázis· Incyte Corp.· Forrás
Toboroz
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
NCT07673887· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00· 3. fázis· Zai Lab (US) LLC· Forrás
Toboroz
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
NCT07549412· 3. fázis· EMD Serono Research & Development Institute, Inc.· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849· 3. fázis· Incyte Corporation· Forrás
Toboroz
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800· 3. fázis· Pfizer· Forrás
Toboroz
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253· 3. fázis· AstraZeneca· Forrás
Toboroz
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled
Antifibrotic Agent
2024-518289-28-00· 2. fázis· Avalyn Pharma Inc.· Forrás
Toboroz
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784· 3. fázis· Revolution Medicines, Inc.· Forrás
Toboroz
A Clinical Study of Arfolitixorin in Patients With mCRC
NCT06922383· 1/2. fázis· Isofol Medical AB· Forrás
Még nem toboroz
Pre-Operative Treatment in REseCTable COlon CanceR
NCT06899477· 3. fázis· Dominik Paul Modest· Forrás
Toboroz
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· 2/3. fázis· BioNTech SE· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· 3. fázis· AstraZeneca· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Toboroz
A pilot study of the safety and tolerability of oral administration of PD L 506 and the subsequent diagnostic value of porphyrin concentration (coproporphyrin I / III, CP I / III) in urine in patients with the first occurrence of colorectal cancer and in healthy subjects.
2023-508668-31-00· 2. fázis· Photonamic GmbH & Co. KG· Forrás
Toboroz
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
2023-509340-10-00· 3. fázis· OSE Immunotherapeutics· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097· 3. fázis· AstraZeneca· Forrás
Toboroz
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401· 2. fázis· Avalyn Pharma Inc.· Forrás
Toboroz
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608· 3. fázis· Summit Therapeutics· Forrás
Fut, nem toboroz
A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326· 2. fázis· Genentech, Inc.· Forrás
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Fut, nem toboroz
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510· 3. fázis· OncoC4, Inc.· Forrás
Fut, nem toboroz
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399· 3. fázis· AstraZeneca· Forrás
Toboroz
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
NCT05008809· 3. fázis· Dominik Paul Modest· Forrás
Fut, nem toboroz
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· 3. fázis· Loxo Oncology, Inc.· Forrás
Fut, nem toboroz
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
NCT04685135· 3. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
NCT04522544· 2. fázis· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Forrás
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
Short RT Versus RCT,Followed by Chemo and Organ Preservation for Interm and High-risk Rectal Cancer Patients
NCT04246684· 3. fázis· Prof. Dr. med. Claus Rödel· Forrás
Fut, nem toboroz
FOLFOX before surgey compared to risk-adapted chemotherapy after surgery in patients with locally advanced rectal cancer and low risk for local failure
NCT04495088· 3. fázis· Heidelberg University· Forrás
Toboroz
An international trial for children with atypical teratoid/rhabdoid tumours (ATRT)
2022-501456-28-00· 3. fázis· GPOH gGmbH· Forrás
Toboroz
International Study for Treatment of High Risk Childhood Relapsed ALL 2010
NCT03590171· 2. fázis· Charite University, Berlin, Germany· Forrás